|
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITINGPhase 1Sponsored by Incyte Corporation
Actively Recruiting
PhasePhase 1
SponsorIncyte Corporation
Started2024-01-04
Est. completion2027-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations16 sites
View on ClinicalTrials.gov →
NCT06179160
Summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * ≥18 years old. * Locally advanced or metastatic solid tumor with KRAS G12D mutation. * For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome. * Cohort specific requirements aas defined in the protocol. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Prior treatment with any KRAS G12D inhibitor * Known additional invasive malignancy within 1 year of the first dose of study drug * History of organ transplant, including allogeneic stem cell transplantation * Significant, uncontrolled medical condition * History or presence of an ECG abnormality * Inadequate organ function Other protocol-defined Inclusion/Exclusion Criteria may apply
Conditions3
CancerLung CancerSolid Tumors
Interventions8
Locations16 sites
Stanford University
UCLA Healthcare Hematology-Oncology
Mayo Clinic Florida
Find trials near these locations
Cancer trials in PhoenixCancer trials in DenverCancer trials in JacksonvilleCancer trials in BaltimoreCancer trials in BostonCancer trials in New YorkCancer trials in PhiladelphiaCancer trials in NashvilleCancer trials in HoustonLung Cancer trials in PhoenixLung Cancer trials in DenverLung Cancer trials in JacksonvilleAll trials in ArizonaAll trials in CaliforniaAll trials in ColoradoAll trials in FloridaAll trials in MarylandAll trials in MassachusettsAll trials in MinnesotaAll trials in New YorkAll trials in PennsylvaniaAll trials in TennesseeAll trials in Texas
Related trials
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer — Tianjin Medical University Cancer Institute and Hospital
- A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers — Hummingbird Bioscience
- A Study of BND-35 in Participants With Advanced Solid Tumors — Biond Biologics
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- AK129 Combination Therapy for Advanced Solid Tumors — Akeso
- ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors — Hansoh BioMedical R&D Company
- BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment — Pierre Fabre Pharma GmbH
- Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study — Sun Yat-sen University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorIncyte Corporation
Started2024-01-04
Est. completion2027-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations16 sites
View on ClinicalTrials.gov →
NCT06179160